MiNK Therapeutics presented new data at a symposium, showing iNKT cell depletion in advanced IPF, supporting the potential of their iNKT platform in chronic lung disease. IPF is a fatal lung disease with no approved treatments. iNKT cells play a role in immune balance and tissue repair, offering new treatment possibilities. The findings suggest that iNKT cell replenishment could help restore immune balance in fibrotic lung disease, addressing a significant unmet medical need. This research expands MiNK’s platform into chronic fibrotic and senescence-associated diseases, offering hope for patients with IPF and other conditions.

Read more at GlobeNewswire: MiNK Therapeutics Presents New Data of allo-iNKT Cell